Zhouwei Zhang1, Donald L Weaver2, Daniel Olsen3, James deKay3, Zhihua Peng4, Takamaru Ashikaga5, Mark F Evans6. 1. Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, Vermont, USA Laboratory of Cancer Epigenetics, Van Andel Research Institute, NE Grand Rapids, Michigan, USA. 2. Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, Vermont, USA Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, Vermont, USA University of Vermont Cancer Center, Burlington, Vermont, USA. 3. Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, Vermont, USA. 4. Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, Vermont, USA. 5. University of Vermont Cancer Center, Burlington, Vermont, USA Biostatistics Unit, University of Vermont College of Medicine, Burlington, Vermont, USA. 6. Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, Vermont, USA University of Vermont Cancer Center, Burlington, Vermont, USA.
Abstract
AIM: Long non-coding RNAs (lncRNAs) are potential biomarkers for breast cancer risk stratification. LncRNA expression has been investigated primarily by RNA sequencing, quantitative reverse transcription PCR or microarray techniques. In this study, six breast cancer-implicated lncRNAs were investigated by chromogenic in situ hybridisation (CISH). METHODS: Invasive breast carcinoma (IBC), ductal carcinoma in situ (DCIS) and normal adjacent (NA) breast tissues from 52 patients were screened by CISH. Staining was graded by modified Allred scoring. RESULTS: HOTAIR, H19 and KCNQ1OT1 had significantly higher expression levels in IBC and DCIS than NA (p<0.05), and HOTAIR and H19 were expressed more strongly in IBC than in DCIS tissues (p<0.05). HOTAIR and KCNQ101T were expressed in tumour cells; H19 and MEG3 were expressed in stromal microenvironment cells; MALAT1 was expressed in all cells strongly and ZFAS1 was negative or weakly expressed in all specimens. CONCLUSION: These data corroborate the involvement of three lncRNAs (HOTAIR, H19 and KCNQ1OT1) in breast tumourigenesis and support lncRNA CISH as a potential clinical assay. Importantly, CISH allows identification of the tissue compartment expressing lncRNA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
AIM: Long non-coding RNAs (lncRNAs) are potential biomarkers for breast cancer risk stratification. LncRNA expression has been investigated primarily by RNA sequencing, quantitative reverse transcription PCR or microarray techniques. In this study, six breast cancer-implicated lncRNAs were investigated by chromogenic in situ hybridisation (CISH). METHODS: Invasive breast carcinoma (IBC), ductal carcinoma in situ (DCIS) and normal adjacent (NA) breast tissues from 52 patients were screened by CISH. Staining was graded by modified Allred scoring. RESULTS:HOTAIR, H19 and KCNQ1OT1 had significantly higher expression levels in IBC and DCIS than NA (p<0.05), and HOTAIR and H19 were expressed more strongly in IBC than in DCIS tissues (p<0.05). HOTAIR and KCNQ101T were expressed in tumour cells; H19 and MEG3 were expressed in stromal microenvironment cells; MALAT1 was expressed in all cells strongly and ZFAS1 was negative or weakly expressed in all specimens. CONCLUSION: These data corroborate the involvement of three lncRNAs (HOTAIR, H19 and KCNQ1OT1) in breast tumourigenesis and support lncRNA CISH as a potential clinical assay. Importantly, CISH allows identification of the tissue compartment expressing lncRNA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Entities:
Keywords:
BREAST CANCER; IN SITU HYBRIDISATION; TUMOUR MARKERS
Authors: Sona Uramova; Peter Kubatka; Zuzana Dankova; Andrea Kapinova; Barbora Zolakova; Marek Samec; Pavol Zubor; Anthony Zulli; Vanda Valentova; Taeg Kyu Kwon; Peter Solar; Martin Kello; Karol Kajo; Dietrich Busselberg; Martin Pec; Jan Danko Journal: EPMA J Date: 2018-11-12 Impact factor: 6.543
Authors: Kirsten M Tracy; Coralee E Tye; Natalie A Page; Andrew J Fritz; Janet L Stein; Jane B Lian; Gary S Stein Journal: J Cell Physiol Date: 2017-06-15 Impact factor: 6.384
Authors: Mark Francis Evans; Pamela Mary Vacek; Brian Lee Sprague; Gary Stephen Stein; Janet Lee Stein; Donald Lee Weaver Journal: J Cell Biochem Date: 2019-10-08 Impact factor: 4.429
Authors: Guangfei Liu; Lu Wang; Hongmin Han; Yong Li; Shouliang Lu; Tiejun Li; Cai Cheng Journal: Am J Cancer Res Date: 2017-07-01 Impact factor: 6.166
Authors: Nithyananda Thorenoor; Petra Faltejskova-Vychytilova; Sonja Hombach; Jitka Mlcochova; Markus Kretz; Marek Svoboda; Ondrej Slaby Journal: Oncotarget Date: 2016-01-05